Sign In
Buy WVE
$5.76
+0.0700 (+1.23%)
At Close: Jun 03, 2026
Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable
Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference
08:30am, Thursday, 29'th May 2025
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.
Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer
08:00am, Wednesday, 28'th May 2025
CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.
Wave Life Sciences Ltd. (WVE) Q1 2025 Earnings Call Transcript
04:57pm, Friday, 09'th May 2025
Wave Life Sciences Ltd. (NASDAQ:WVE ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Kate Rausch - Vice President, Investor Relations & Corporate Affairs Paul Bolno - Pre
Wave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue Estimates
09:50am, Thursday, 08'th May 2025
Wave Life Sciences (WVE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.24 per share a year ago.
Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
07:30am, Thursday, 08'th May 2025
Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track f
Analysts Estimate Wave Life Sciences (WVE) to Report a Decline in Earnings: What to Look Out for
11:07am, Thursday, 01'st May 2025
Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025
08:30am, Thursday, 01'st May 2025
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform
Promising Genomics & Synthetic Biology Stocks to Consider in 2025
10:41am, Friday, 28'th Mar 2025
Investors interested in the Genomics and Synthetic Biology theme should consider these stocks: Twist Bioscience Corporation, Wave Life Sciences, and CRISPR Therapeutics AG.
Wave Life Sciences: Potential For Accelerated Approval Pathway With WVE-N531
03:54pm, Thursday, 27'th Mar 2025
Wave Life Sciences Ltd. release of multi-dose data from the phase 1b/2a open-label RestorAAtion-2 study, using WVE-006 for AATD-related lung disease, expected in 2025. Positive results were achieved i
Wave Life Sciences (WVE) Stock Jumps 6.1%: Will It Continue to Soar?
06:35am, Thursday, 27'th Mar 2025
Wave Life Sciences (WVE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near ter
Wave Life Sciences Stock Jumps On Positive Data From Muscle Disorder Drug, Plans FDA Submission Next Year
10:21am, Wednesday, 26'th Mar 2025
Wave Life Sciences Ltd. WVE released data from the Phase 2 FORWARD-53 trial of WVE-N531, which is an exon-skipping oligonucleotide being investigated in boys with Duchenne muscular dystrophy (DMD) wh
Statistically significant and clinically meaningful improvement of 3.8 seconds in Time-to-Rise vs. natural history with largest effect observed relative to any approved dystrophin restoration therapy
Wave Life Sciences Ltd. (WVE) Q4 2024 Earnings Call Transcript
03:16pm, Tuesday, 04'th Mar 2025
Wave Life Sciences Ltd. (NASDAQ:WVE ) Q4 2024 Earnings Conference Call March 4, 2025 8:30 AM ET Company Participants Kate Rausch - VP, IR & Corporate Affairs Paul Bolno - President & CEO Erik Ingelsso
Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
07:30am, Tuesday, 04'th Mar 2025
Dosing underway in INLIGHT trial of WVE-007 in obesity with clinical data expected in 2H 2025; enrollment complete in first single dose cohort
